AARD vs KIM · $284.4M cap vs P/E 27, rev $1.11B
Aardvark Therapeutics, Inc. Common Stock (AARD) versus Kimco Realty Corporation (KIM) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
Kimco Realty Corporation (KIM) is a reit - retail company listed on US.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported KIM revenue for 2026-06-30 was $1.11B. Net income was $318.2M. Revenue was up 98.7% from 2026-03-31 to 2026-06-30. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
AARD currently screens at market cap $284.4M. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
Not investment advice. Open the AARD and KIM stock pages for the full models.
Not investment advice.